United Kingdom· GB-APID-14739611000001100
Neostigmine 2.5mg/1ml / Glycopyrronium bromide 500micrograms/1ml solution for injection ampoules
A medicinal product containing neostigmine + glycopyrronium bromide, registered in United Kingdom by A A H Pharmaceuticals Ltd.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Neostigmine + Glycopyrronium bromide
- Manufacturer
- A A H Pharmaceuticals Ltd
- Country
- United Kingdom (GB)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f5efe452-3259-4784-ad47-e0213e6990ff GET /v1/drugs/f5efe452-3259-4784-ad47-e0213e6990ff?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "14739611000001100",
"desc": "Neostigmine 2.5mg/1ml / Glycopyrronium bromide 500micrograms/1ml solution for injection ampoules (A A H Pharmaceuticals Ltd)",
"form": "Solution for injection",
"vpid": "36030711000001107",
"source": "dmd",
"vtm_id": "35312711000001103",
"strength": "2.5 mg",
"substance": "Neostigmine + Glycopyrronium bromide",
"ingredient": "Neostigmine metilsulfate",
"supplier_code": "3144701000001104"
}See everything about neostigmine + glycopyrronium bromide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.